Deferred Royalty Obligation related to the Sale of Future Royalties - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Deferred Royalty Obligation [Line Items]
Non-cash interest expense on deferred royalty obligation		$ 9,900	$ 9,700	$ 19,329	$ 18,991
Percentage of interest rate amortize liability		17.03%		17.03%
Blackstone Life Sciences
Deferred Royalty Obligation [Line Items]
Upfront payment received	$ 140,000
Blackstone Life Sciences \| Maximum
Deferred Royalty Obligation [Line Items]
Milestone payment receivable	250,000
2015 License Agreement \| Blackstone Life Sciences
Deferred Royalty Obligation [Line Items]
Transaction costs incurred	3,800
2015 License Agreement \| Blackstone Life Sciences \| Royalty
Deferred Royalty Obligation [Line Items]
Upfront payment received	$ 140,000
Revenue interest percentage	4.00%			4.00%		4.00%
Amendment 3 2015 License Agreement \| Vaxcyte \| Royalty
Deferred Royalty Obligation [Line Items]
Revenue interest percentage				4.00%